


Arun K. Ghosh and Sandra Gemma

Structure-based Design of Drugs and Other Bioactive Molecules

Tools and Strategies



Arun K. Ghosh and Sandra Gemma

**Structure-based Design of Drugs and
Other Bioactive Molecules**

Related Titles

Li, J. J., Corey, E.J. (eds.)

Drug Discovery

Practices, Processes, and Perspectives

2013

ISBN: 978-0-470-94235-2 (Also available
in electronic formats)

Brown, N. (ed.)

Scaffold Hopping in Medicinal Chemistry

2014

ISBN: 978-3-527-33364-6 (Also available
in electronic formats)

Schneider, G. (ed.)

De novo Molecular Design

2014

ISBN: 978-3-527-33461-2 (Also available in electronic formats)

Young, D.C.

Computational Drug Design

A Guide for Computational and Medicinal Chemists (with CD-Rom)

2009

Print ISBN: 978-0-470-12685-1 (Also available in electronic formats)

Arun K. Ghosh and Sandra Gemma

Structure-based Design of Drugs and Other Bioactive Molecules

Tools and Strategies

WILEY-VCH
Verlag GmbH & Co. KGaA

The Authors

Prof. Dr. Arun K. Ghosh

Purdue University
Department of Chemistry
and Department of Medicinal Chemistry
560 Oval Drive
West Lafayette, IN
United States

Prof. Dr. Sandra Gemma

Università degli Studi Siena
Dipartimento di Biotecnologie, Chimica e
Farmacia
via Aldo Moro 2
53100 Siena
Italy

All books published by **Wiley-VCH** are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.: applied for

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <<http://dnb.d-nb.de>>.

© 2014 Wiley-VCH Verlag GmbH & Co. KGaA,
Boschstr. 12, 69469 Weinheim, Germany

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Print ISBN: 978-3-527-33365-3

ePDF ISBN: 978-3-527-66524-2

ePub ISBN: 978-3-527-66523-5

Mobi ISBN: 978-3-527-66522-8

oBook ISBN: 978-3-527-66521-1

Cover Design Bluesea Design, McLeese Lake,
Canada

Typesetting Thomson Digital, Noida, India

Printing and Binding Markono Print Media Pte Ltd,
Singapore

Printed on acid-free paper

Contents

Preface *XIII*

1 From Traditional Medicine to Modern Drugs: Historical Perspective of Structure-Based Drug Design 1

- 1.1 Introduction 1
- 1.2 Drug Discovery During 1928–1980 1
- 1.3 The Beginning of Structure-Based Drug Design 6
- 1.4 Conclusions 12
- References 13

Part One Concepts, Tools, Ligands, and Scaffolds for Structure-Based Design of Inhibitors 19

2 Design of Inhibitors of Aspartic Acid Proteases 21

- 2.1 Introduction 21
- 2.2 Design of Peptidomimetic Inhibitors of Aspartic Acid Proteases 22
- 2.3 Design of Statine-Based Inhibitors 24
- 2.4 Design of Hydroxyethylene Isostere-Based Inhibitors 29
- 2.5 Design of Inhibitors with Hydroxyethylamine Isosteres 35
- 2.5.1 Synthesis of Optically Active α -Aminoalkyl Epoxide 37
- 2.6 Design of (Hydroxyethyl)urea-Based Inhibitors 40
- 2.7 (Hydroxyethyl)sulfonamide-Based Inhibitors 42
- 2.8 Design of Heterocyclic/Nonpeptidomimetic Aspartic Acid Protease Inhibitors 42
- 2.8.1 Hydroxycoumarin- and Hydroxypyrrone-Based Inhibitors 44
- 2.8.2 Design of Substituted Piperidine-Based Inhibitors 46
- 2.8.3 Design of Diaminopyrimidine-Based Inhibitors 50
- 2.8.4 Design of Acyl Guanidine-Based Inhibitors 51
- 2.8.5 Design of Aminopyridine-Based Inhibitors 53
- 2.8.6 Design of Aminoimidazole- and Aminohydantoin-Based Inhibitors 53
- 2.9 Conclusions 56
- References 56

3	Design of Serine Protease Inhibitors	67
3.1	Introduction	67
3.2	Catalytic Mechanism of Serine Protease	67
3.3	Types of Serine Protease Inhibitors	67
3.4	Halomethyl Ketone-Based Inhibitors	69
3.5	Diphenyl Phosphonate-Based Inhibitors	70
3.6	Trifluoromethyl Ketone Based Inhibitors	73
3.6.1	Synthesis of Trifluoromethyl Ketones	76
3.7	Peptidyl Boronic Acid-Based Inhibitors	78
3.7.1	Synthesis of α -Aminoalkyl Boronic Acid Derivatives	83
3.8	Peptidyl α -Ketoamide- and α -Ketoheterocycle-Based Inhibitors	85
3.8.1	Synthesis of α -Ketoamide and α -Ketoheterocyclic Templates	90
3.9	Design of Serine Protease Inhibitors Based Upon Heterocycles	93
3.9.1	Isocoumarin-Derived Irreversible Inhibitors	94
3.9.2	β -Lactam-Derived Irreversible Inhibitors	95
3.10	Reversible/Noncovalent Inhibitors	97
3.11	Conclusions	104
	References	105
4	Design of Proteasome Inhibitors	113
4.1	Introduction	113
4.2	Catalytic Mechanism of 20S Proteasome	113
4.3	Proteasome Inhibitors	114
4.3.1	Development of Boronate Proteasome Inhibitors	115
4.3.2	Development of β -Lactone Natural Product-Based Proteasome Inhibitors	116
4.3.3	Development of Epoxy Ketone-Derived Inhibitors	118
4.3.4	Noncovalent Proteasome Inhibitors	120
4.4	Synthesis of β -Lactone Scaffold	121
4.5	Synthesis of Epoxy Ketone Scaffold	123
4.6	Conclusions	126
	References	126
5	Design of Cysteine Protease Inhibitors	131
5.1	Introduction	131
5.2	Development of Cysteine Protease Inhibitors with Michael Acceptors	132
5.3	Design of Noncovalent Cysteine Protease Inhibitors	136
5.4	Conclusions	140
	References	140
6	Design of Metalloprotease Inhibitors	143
6.1	Introduction	143
6.2	Design of Matrix Metalloprotease Inhibitors	144

6.3	Design of Inhibitors of Tumor Necrosis Factor- α -Converting Enzymes	150
6.4	Conclusions	152
	References	152
7	Structure-Based Design of Protein Kinase Inhibitors	155
7.1	Introduction	155
7.2	Active Site of Protein Kinases	155
7.3	Catalytic Mechanism of Protein Kinases	156
7.4	Design Strategy for Protein Kinase Inhibitors	156
7.5	Nature of Kinase Inhibitors Based upon Binding	160
7.5.1	Type I Kinase Inhibitors and Their Design	160
7.5.2	Type II Kinase Inhibitors and Their Design	164
7.5.3	Allosteric Kinase Inhibitors and Their Design	168
7.5.4	Covalent Kinase Inhibitors and Their Design	172
7.6	Conclusions	177
	References	177
8	Protein X-Ray Crystallography in Structure-Based Drug Design	183
8.1	Introduction	183
8.2	Protein Expression and Purification	184
8.3	Synchrotron Radiation	185
8.4	Structural Biology in Fragment-Based Drug Design	186
8.5	Selected Examples of Fragment-Based Studies	187
8.6	Conclusions	196
	References	197
9	Structure-Based Design Strategies for Targeting G-Protein-Coupled Receptors (GPCRs)	199
9.1	Introduction	199
9.2	High-Resolution Structures of GPCRs	200
9.3	Virtual Screening Applied to the β_2 -Adrenergic Receptor	201
9.4	Structure-Based Design of Adenosine A _{2A} Receptor Antagonists	204
9.5	Structure-Guided Design of CCR5 Antagonists	207
9.5.1	Development of Maraviroc from HTS Lead Molecules	207
9.5.2	Improvement of Antiviral Activity and Reduction of Cytochrome P450 Activity	208
9.5.3	Reduction of hERG Activity and Optimization of Pharmacokinetic Profile	209
9.5.4	Other CCR5 Antagonists	213
9.6	Conclusion	213
	References	213

Part Two Structure-Based Design of FDA-Approved Inhibitor Drugs and Drugs Undergoing Clinical Development 217

- 10 Angiotensin-Converting Enzyme Inhibitors for the Treatment of Hypertension: Design and Discovery of Captopril 219**
 - 10.1 Introduction 219
 - 10.2 Design of Captopril: the First Clinically Approved Angiotensin-Converting Enzyme Inhibitor 220
 - 10.3 Structure of Angiotensin-Converting Enzyme 225
 - 10.4 Design of ACE Inhibitors Containing a Carboxylate as Zinc Binding Group 228
 - 10.5 ACE Inhibitors Bearing Phosphorus-Based Zinc Binding Groups 231
 - 10.5.1 Phosphoramidate-Based Inhibitors 232
 - 10.5.2 Phosphonic and Phosphinic Acid Derivatives: the Path to Fosinopril 233
 - 10.6 Conclusions 234
 - References 235
- 11 HIV-1 Protease Inhibitors for the Treatment of HIV Infection and AIDS: Design of Saquinavir, Indinavir, and Darunavir 237**
 - 11.1 Introduction 237
 - 11.2 Structure of HIV Protease and Design of Peptidomimetic Inhibitors Containing Transition-State Isosteres 239
 - 11.3 Saquinavir: the First Clinically Approved HIV-1 Protease Inhibitor 241
 - 11.4 Indinavir: an HIV Protease Inhibitor Containing the Hydroxyethylene Transition-State Isostere 246
 - 11.5 Design and Development of Darunavir 251
 - 11.6 Design of Cyclic Ether Templates in Drug Discovery 252
 - 11.7 Investigation of Cyclic Sulfones as P_2 Ligands 255
 - 11.8 Design of Bis-tetrahydrofuran and Other Bicyclic P_2 Ligands 257
 - 11.9 The “Backbone Binding Concept” to Combat Drug Resistance: Inhibitor Design Strategy Promoting Extensive Backbone Hydrogen Bonding from S_2 to S_2' Subsites 259
 - 11.10 Design of Darunavir and Other Inhibitors with Clinical Potential 263
 - 11.11 Conclusions 266
 - References 266
- 12 Protein Kinase Inhibitor Drugs for Targeted Cancer Therapy: Design and Discovery of Imatinib, Nilotinib, Bafetinib, and Dasatinib 271**
 - 12.1 Introduction 271
 - 12.2 Evolution of Kinase Inhibitors as Anticancer Agents 272
 - 12.3 The Discovery of Imatinib 274
 - 12.4 Imatinib: the Structural Basis of Selectivity 275
 - 12.5 Pharmacological Profile and Clinical Development 278

12.6	Imatinib Resistance	279
12.7	Different Strategies for Combating Drug Resistance	279
12.7.1	Nilotinib and Bafetinib: Optimizing Drug–Target Interactions	279
12.7.2	Dasatinib: Binding to the Active Conformation (the First Example of Dual Abl/Src Inhibitors)	284
12.8	Conclusions	289
	References	290
13	NS3/4A Serine Protease Inhibitors for the Treatment of HCV: Design and Discovery of Boceprevir and Telaprevir	295
13.1	Introduction	295
13.2	NS3/4A Structure	296
13.3	Mechanism of Peptide Hydrolysis by NS3/4A Serine Protease	299
13.4	Development of Mechanism-Based Inhibitors	300
13.5	Strategies for the Development of HCV NS3/4A Protease Inhibitors	303
13.6	Initial Studies toward the Development of Boceprevir	304
13.7	Reduction of Peptidic Character	308
13.8	Optimization of P ₂ Interactions	309
13.9	Truncation Strategy: the Path to Discovery of Boceprevir	312
13.10	The Discovery of Telaprevir	314
13.11	Simultaneous P ₁ , P ₁ ', P ₂ , P ₃ , and P ₄ Optimization Strategy: the Path to Discovery of Telaprevir	316
13.12	Conclusions	319
	References	319
14	Proteasome Inhibitors for the Treatment of Relapsed Multiple Myeloma: Design and Discovery of Bortezomib and Carfilzomib	325
14.1	Introduction	325
14.2	Discovery of Bortezomib	326
14.3	Discovery of Carfilzomib	330
14.4	Conclusions	334
	References	334
15	Development of Direct Thrombin Inhibitor, Dabigatran Etexilate, as an Anticoagulant Drug	337
15.1	Introduction	337
15.2	Coagulation Cascade and Anticoagulant Drugs	338
15.3	Anticoagulant Therapies	340
15.4	Structure of Thrombin	342
15.5	The Discovery of Dabigatran Etexilate	345
15.6	Conclusions	353
	References	353

16	Non-Nucleoside HIV Reverse Transcriptase Inhibitors for the Treatment of HIV/AIDS: Design and Development of Etravirine and Rilpivirine	355
16.1	Introduction	355
16.2	Structure of the HIV Reverse Transcriptase	357
16.3	Discovery of Etravirine and Rilpivirine	360
16.4	Conclusions	368
	References	370
17	Renin Inhibitor for the Treatment of Hypertension: Design and Discovery of Aliskiren	373
17.1	Introduction	373
17.2	Structure of Renin	373
17.3	Peptidic Inhibitors with Transition-State Isosteres	374
17.4	Peptidomimetic Inhibitors	376
17.5	Design of Peptidomimetic Inhibitors	380
17.6	Biological Properties of Aliskiren	393
17.7	Conclusions	393
	References	394
18	Neuraminidase Inhibitors for the Treatment of Influenza: Design and Discovery of Zanamivir and Oseltamivir	397
18.1	Introduction	397
18.2	Discovery of Zanamivir	401
18.3	Discovery of Oseltamivir	403
18.4	Conclusions	407
	References	408
19	Carbonic Anhydrase Inhibitors for the Treatment of Glaucoma: Design and Discovery of Dorzolamide	411
19.1	Introduction	411
19.2	Design and Discovery of Dorzolamide	412
19.3	Conclusions	418
	References	418
20	β-Secretase Inhibitors for the Treatment of Alzheimer's Disease: Preclinical and Clinical Inhibitors	421
20.1	Introduction	421
20.2	β -Secretase and Its X-Ray Structure	422
20.3	Development of First Peptidomimetic BACE Inhibitors	423
20.4	X-Ray Structure of Inhibitor-Bound BACE1	425
20.5	Design and Development of Selective Inhibitors	427
20.6	Design of Small-Molecule Inhibitors with Clinical Potential	431
20.7	GRL-8234 (18) Rescued Cognitive Decline in AD Mice	435
20.8	BACE1 Inhibitors for Clinical Development	436

20.8.1	Development of Clinical Inhibitor, AZD3839	436
20.8.2	Development of Iminopyrimidinone-Based BACE1 Inhibitors	440
20.9	Conclusions	443
	References	444

Index	449
--------------	-----

Preface

As our knowledge of the structure and function of proteins has expanded, new techniques employing this knowledge as the basis for drug design and discovery have emerged and taken the lead. The impact of structure-based design strategies has been dramatic and far-reaching, resulting in the discovery and development of numerous FDA-approved drugs, many of which are first-in-class medicines. Major advancements in molecular biology and technology have led to in-depth structural knowledge of new disease-relevant target enzymes. Improvements in X-ray crystallographic techniques have created an important database and enabled a better understanding of the role of enzyme–ligand interactions. Progress in computer analysis has also played a vital role in advancing structure-based design capabilities since the 1980s. Today, structure-based design has become one of the most innovative and dynamic areas of drug design and discovery.

Over the years, the Ghosh laboratories have gained extensive experience with structure-based design. The development of conceptually novel inhibitors against HIV-1 protease for the treatment of HIV/AIDS has been an important area of research that led to the design and discovery of darunavir, the first FDA-approved treatment for drug-resistant HIV/AIDS. Structure-based design of β -secretase 1 (BACE1) inhibitors for the treatment of Alzheimer's disease also started in the Ghosh laboratories with the design and synthesis of the first substrate-based transition-state inhibitors, determination of the first X-ray crystal structure of inhibitor-bound BACE1, followed by design and development of potent and selective inhibitors with clinical potential. The Ghosh laboratories have also led the design of coronavirus 3CLPro and PLpro inhibitors for possible treatment of SARS/Mers and the design of methyltransferase inhibitors for possible treatment of dengue virus infection. Our experience in structure-based design in these diverse areas is detailed within this book.

A significant body of structure-based design work for many approved therapeutic drugs and preclinical and clinical candidates has been reported by numerous academic and pharmaceutical scientists. This work has led to the development of tools, strategies, and concepts that aid the process of structure-based design. A substantial part of this work has been an integral part of the lecture notes of one of the authors for teaching fundamentals and concepts of drug discovery and design to students at Purdue University. During these research and teaching endeavors, an

important need for writing this book was recognized. Although there are many elegant reports of the structure-based design of therapeutic drugs that span three decades now, a systematic presentation of the evolution of the field, principles, and applications had not yet been compiled. The materials of this treatise are organized with these objectives in mind. This book covers a critical overview of the history of structure-based drug design, an analysis of the underlying principles, and an up-to-date description of the X-ray techniques and methods that led to the structure determination of many important biomolecules. The book also highlights the structure-based design and drug development process covering a broad array of FDA-approved medications. The reader will gain a sense of how a drug interacts with its biological target at the molecular level and how the drug–target interactions can be optimized in order to increase affinity with desired physicochemical and drug-like properties. Furthermore, the reader will gain knowledge of how other factors such as *in vivo* efficacy and physicochemical and pharmacokinetic parameters need to be optimized in order to convert a lead compound into a clinical drug structure.

Chapter 1 provides a historical perspective of drug discovery encompassing discovery through serendipity and natural product screening to the evolution of the field of structure-based design of today's medicines. Chapters 2–7 outline general principles for design of enzyme inhibitors covering aspartic acid proteases, serine proteases, cysteine proteases, metalloproteases, threonine proteases, and protein kinases. These chapters highlight the key protein–ligand interactions and evolution of ligands, scaffolds, and templates to aid molecular design of lead inhibitors and their optimization. These chapters also cover the synthesis of a selection of ligands, templates, and isosteres generally utilized for structure-based design. Chapter 8 reviews recent progress in gaining high-resolution structural knowledge of biologically relevant proteins and G-protein-coupled receptors (GPCRs), particularly the methods of X-ray crystallography and their application in lead discovery. Chapter 9 covers recent developments in the structure-based design of novel ligands for GPCRs, an exciting new dimension for GPCR research.

Chapters 10–20 cover an array of recently FDA-approved drugs developed by utilizing structure-based design strategies. These chapters highlight the mechanism of action associated with each drug class, in-depth structural analysis of protein–ligand interactions, structural design, and optimization of ligand binding to protein structures. Chapter 10 is devoted to the design of the first ACE inhibitor, captopril, which marks the beginning of structure-based design. Chapters 11–19 cover the design and development of HIV-1 protease inhibitors such as saquinavir, indinavir, and darunavir (Chapter 11); kinase inhibitor drugs imatinib, nilotinib, and dasatinib (Chapter 12); NS3/4A serine protease inhibitor drugs boceprevir and telaprevir for the treatment of HCV (Chapter 13); proteasome inhibitor drugs bortezomib and carfilzomib for the treatment of relapsed multiple myeloma (Chapter 14); development of direct thrombin inhibitor dabigatran etexilate (Chapter 15); non-nucleoside HIV reverse-transcriptase inhibitors etravirine and rilpivirine (Chapter 16); development of renin inhibitor aliskiren (Chapter 17); neuraminidase inhibitors zanamivir and oseltamivir for the treatment of influenza (Chapter 18); and carbonic

anhydrase inhibitor dorzolamide (Chapter 19) for the treatment of glaucoma. The last chapter outlines the development of β -secretase inhibitors that are at various stages of preclinical and clinical development for possible treatment of Alzheimer's disease.

Overall, this book will greatly enhance the readers' understanding of structure-based design and drug discovery, its potential, underlying principles, feasibility, and limitations. We believe that the book will be an excellent resource for new and practicing medicinal chemists, biologists, biochemists, and pharmacologists who are interested in working in the field of molecular design for discovery and development of human medicine. Structure-based design has a critical role in today's drug design and discovery, and it will continue to play a very prominent role in drug design and medicinal chemistry endeavors throughout the twenty-first century. We hope that the book will be helpful to researchers involved in drug discovery and the pursuit of knowledge in structure-based design and related areas.

We gratefully acknowledge the National Institutes of Health for financial support of our research work.

We very much enjoyed working with Drs. Frank Weinreich and Lesley Belfit and the Wiley-VCH editorial team. We sincerely appreciate their help and support throughout this project. We would like to thank Dr. Hiroaki Mitsuya, Dr. Jordan Tang and Dr. Irene Weber for longstanding and productive research collaboration. We would like to express our appreciation and thanks to our research colleagues from Purdue University, Dr. Venkateswararao Kalapala, Dr. Navanth Gavande, Ms. Heather Osswald, Mr. Anindya Sarkar, Ms. Kelsey Cantwell and Mr. Anthony Tomaine for their invaluable help with proofreading and reviewing of this work. We wish to convey special thanks and appreciation to Dr. Jody Ghosh for her help and support and Mrs. JoAnna Hadley for her help with the manuscript preparation and organization. Finally, we wish to thank our families for their love, support, and inspiration.

Purdue University
Purdue University & University of Siena

Arun K. Ghosh
Sandra Gemma

1

From Traditional Medicine to Modern Drugs: Historical Perspective of Structure-Based Drug Design

1.1

Introduction

The drug design and discovery process of today is a highly interdisciplinary research endeavor [1–3]. Advances in molecular biology, synthetic chemistry, and pharmacology, as well as technological breakthroughs in X-ray crystallography and computational methods have brought dramatic changes to medicinal chemistry practices during the late twentieth century. Drug design efforts based upon the three-dimensional structure of a target enzyme have become the hallmark of modern molecular design strategies. This structure-based design approach has revolutionized the practice of medicinal chemistry and recast the preclinical drug discovery process. Many of the FDA-approved drugs have evolved through structure-based design strategies. By 2012, as many as 35 newly approved drugs have emanated from structure-based design. The post-genomic era holds huge promise for the advancement of structure-based design of drugs for new therapies. Human genome sequencing has now revealed that there are an estimated 20,000–25,000 protein-coding human genes, and each gene can code for one protein. These proteins are responsible for carrying out all the cellular functions in the human body. These proteins can also be involved in disease pathologies, providing unique opportunities and challenges for structure-based design of new drugs. It may be appropriate to review briefly how the first half of the twentieth century was shaped and enriched by a number of seminal discoveries and the advent of new technologies, all of which left an important imprint on today's drug discovery and medicinal chemistry. A number of previous reviews have provided some insight [4,5].

1.2

Drug Discovery During 1928–1980

The history of medicinal chemistry is marked by examples in which the discovery of novel drugs relied upon serendipity and clinical observations. It is interesting to consider the role of chance in unexpected and accidental scientific discoveries. This serendipity is not simply luck. Rather, it is a process of finding significance

and value in the lucky coincidence. As Pasteur observed, “Chance favors the prepared mind.” Without engaging creative thinking and analysis, accidents do not lead to discoveries. The discovery of penicillin is a famous example of serendipity [6,7]. Alexander Fleming departed for a vacation in the summer of 1928. He left a bacterial culture of *Staphylococcus aureus* on his laboratory bench. When he returned a month later, he found that the culture was contaminated by a patch of blue-green mold that caused the lysis of bacteria. Fleming later demonstrated that the mold, *Penicillium notatum*, produced an active ingredient that he called penicillin. The discovery of penicillin was particularly fortunate since the penicillin that landed on Fleming’s bacterial culture was not ordinary *Penicillium*! If it were, it would not have produced penicillin in high enough concentrations to cause the lysis of bacteria.

The discovery of penicillin was not mere luck. Much more subsequent investigation was required before it could be used as an antibiotic. More than a decade later in the 1940s, Howard Florey and Ernest Chain, with their Oxford team, unveiled its therapeutic potential. During this time, fermentation methods were developed that allowed the effective application of penicillins (Figure 1.1) for the treatment of bacterial infections in humans. Bactericidal penicillin rapidly replaced the bacteriostatic sulfonamide drugs used until then for the treatment of some bacterial infections.

The discovery of bacteriostatic sulfonamides has its own interesting story of serendipity and intuition [8]. The dye industry was advanced and promoted chemical manufacturing to develop new dyes. German chemists working with azo dyes observed that certain dyes could preferentially stick to and stain bacterial colonies. Could this serve as a way to target bacteria? In 1935, the German biochemist Gerhard Domagk, assisted by a group of chemists, synthesized and tested hundreds of dyes and finally discovered, by a trial-and-error approach, the potent




Figure 1.1 Structures of penicillins G and V and semisynthetic penicillins.




Figure 1.2 Structures of prontosil and its derivative.

antibacterial activity of Prontosil rubrum (Figure 1.2). Subsequent studies revealed that the active moiety of the compound was the 4-aminobenzenesulfonamide moiety. Introduction of substituents at both the *p*-aniline and the sulfonamide groups led to the development of new sulfanilide derivatives with broad-spectrum activity, improved pharmacokinetic properties, and lowered therapeutic side effects. The synthesis of new derivatives became less important due to the discovery and introduction of penicillin and subsequently discovered antibiotics.

Research on sulfonamide derivatives, however, continued. Close observation of side effects led to the development of new uses and expansion of this class of compounds. The clinical observation that sulfa drugs induced hypoglycemia was followed by studies aimed at maximizing this side effect and dissociating it from the bacteriostatic activity. This led to the advent of oral hypoglycemia drugs for the treatment of diabetes. In 1940, Mann and Keilin discovered the inhibitory activity of sulfanilamide against carbonic anhydrase. This key discovery paved the way for the subsequent development of diuretic sulfonamides [9].

The discovery of the antidepressant agent iproniazid is also due to the clinical observation of a “side effect” [10]. Both isoniazid (Figure 1.3) and its isopropyl-substituted derivative iproniazid were originally developed as tuberculostatic drugs. However, it was observed that in contrast to isoniazid, patients treated with




Figure 1.3 Structures of isoniazids, minoxidil, and sildenafil.

iproniazid experienced elevation of mood. Subsequent studies clarified that the antidepressant activities of iproniazid were due to the inhibition of the centrally active enzyme monoamine oxidase (MAO). Iproniazid was approved in 1958 for the treatment of depression. There are also more recent examples of clinical observations leading to the discovery of new drugs. Sildenafil or Viagra, a drug used for the treatment of erectile dysfunction, was originally developed for the treatment of angina [11,12]. Minoxidil [13,14], originally developed as an antihypertensive agent, was later approved for the treatment of hair loss.

Serendipity also played a role in the discovery of Librium, the first antianxiety benzodiazepine, but it did not happen by accident [15,16]. In 1954, Dr. Leo Sternbach was actively involved in the development of new tranquilizers in the New Jersey laboratories of Hoffmann-La Roche. He decided to explore the chemistry of benzheptodiazines, a class of compounds he had synthesized 20 years ago in search of new dyes but whose biological activity was unknown. His research group synthesized 40 new derivatives and determined that they were six-membered ring compounds such as **11** and **12** (Figure 1.4) rather than seven-membered ring compounds **13** and **14**, as was originally thought. Pharmacological testing showed these compounds were inactive. As their project on tranquilizers was coming to an end, during their laboratory cleanup work, they realized two of their earlier crystalline derivatives had never been submitted for pharmacological evaluation. They decided to send them for biological testing. One of the compounds that resulted from the reaction of a quinazoline derivative **15** with methylamine showed potent sedative and hypnotic effects. This compound was superior to phenobarbital. Subsequent structural work on the compound led to its characterization as benzodiazepine derivative chlordiazepoxide (**17**, Figure 1.5) known as Librium. This resulted from a rearrangement of the original benzo-fused six-membered heterocycle to afford a benzo-fused seven-membered




Figure 1.4 Structures of benzheptodiazines and quinazoline-3-oxides.




Figure 1.5 Structures of benzodiazepine derivatives, Librium and Valium.

heterocycle **17**. This discovery led to the subsequent development of a host of benzodiazepines, including diazepam (**18**, Valium).

Natural products have long served as a key source for the development of numerous new drugs. Biological screening of natural products has proven to be extremely useful. The anticancer agent Taxol was discovered in the 1970s as a result of a project implemented in 1960 by the American National Cancer Institute consisting of the biological screening of extracts arising from various natural sources [17]. One of the extracts showed promising anticancer activity against a wide range of tumors in mice. After the initial discovery, the active compound was isolated from the *Taxus brevifolia* and in 1972 its chemical structure (**19**, Figure 1.6) was fully characterized [18]. Another important anticancer treatment resulting from the screening of natural products was camptothecin (**20**), which was isolated from *Camptotheca acuminata* [19]. A number of camptothecin derivatives have been approved and are used in cancer chemotherapy.

The antimalarial drug artemisinin (**21**, Figure 1.7) [20] is also the result of a screening campaign. After a heavy outbreak of malaria in the 1950s, the spread of




Figure 1.6 Structures of Taxol and camptothecin.




Figure 1.7 Structures of artemisinin and mevinolin and their derivatives.

drug-resistant malaria strains raised huge treatment concerns. A Chinese national project implemented a campaign aimed at discovering, isolating, and characterizing natural products as potential antimalarial leads. Phytochemist Tu Youyou and his colleagues found that the extract of the traditional Chinese herbal remedy *Artemisia annua* was effective in a mouse model against malaria. Later, the sesquiterpene lactone artemisinin was characterized as the active ingredient and its semisynthetic derivatives, such as artemether (22), are used for the treatment of multidrug-resistant malaria.

During the 1970s, a number of other important natural products were also introduced as new drugs. Natural products compactin and mevinolin were isolated from *Penicillium citrinum* and *Aspergillus terreus*, respectively. Both these natural products showed very potent inhibitory activity of HMG-CoA reductase, responsible for biosynthesis of cholesterol in human liver. Mevinolin (lovastatin) and derivatives of mevinolin (Zocor) were introduced for the treatment of atherosclerosis by lowering cholesterol levels and inhibiting the enzyme HMG-CoA reductase [21,22].

1.3

The Beginning of Structure-Based Drug Design

During the late 1970s, rational design evolved into a strategy for the discovery and development of new drugs. With the knowledge of the three-dimensional structure of drug targets and their site of interaction with a prototype drug molecule or

ligand, logical molecular design based upon target–ligand interactions began to take shape. Early during this practice, X-ray structural information was limited. The X-ray structural data of related enzymes were used to model the target enzyme. Advances in technology and molecular biology greatly enhanced the promise of structure-based design. During the 1980s, rapid progress in protein expression, purification, and protein crystallography provided detailed structural knowledge of disease-relevant target proteins. The progress of chemical synthesis was timely as well. New and efficient reagents, protecting groups, catalytic transformations, and multistep chemical synthetic strategies provided the power of creative design capabilities for structure-based design. Drug design through structure-based approaches rapidly revolutionized the field of medicinal chemistry and changed the approach toward the identification and optimization of novel drugs.

In structure-based design, the shape and the electronic features for the binding site of a specific target protein are generated early on. Also, the crystal structures of protein and ligand complexes are determined to obtain information on intermolecular interactions within the protein active site. This molecular insight often provides the bioactive conformation of the ligand for molecular design [23,24]. Starting from this key information, structure-based design strategies allow the optimization of ligand–protein interactions to improve potency, affinity, and selectivity, while at the same time preserving and optimizing selected drug-like properties.

An early example of rational design utilizing structural information of an enzyme–inhibitor interaction can be traced to the discovery of the angiotensin-converting enzyme (ACE) inhibitor, captopril [25]. Although the X-ray structure of the actual ACE was unknown at that time, the structure of a similar enzyme, carboxypeptidase A, had already been determined. Both carboxypeptidase A and ACE have a number of common features, including the presence of a zinc ion in the protease active site. Based on this structural knowledge and a number of peptidic lead ACE inhibitors from snake venoms, investigators at Bristol-Myers Squibb (BMS) modeled the active site of ACE and rationally designed captopril, the first FDA-approved ACE inhibitor for the treatment of hypertension in 1981.

The clinical success of ACE inhibitors fueled a great deal of interest in the development of inhibitor drugs against renin, an aspartic acid protease [26]. Renin is responsible for the regulation of blood pressure, and therapeutic inhibition of renin was considered a promising strategy for the development of novel therapies for the treatment of hypertension. It was presumed that a successful renin inhibitor would possess fewer side effects than ACE inhibitors due to the exquisite selectivity of renin for a single physiological substrate. Key information in the development of renin inhibitors was the understanding of the substrate cleavage mechanism and the characterization of the endogenous peptide binding site [27–29]. The X-ray structure of renin was not known; however, a model structure of renin was created based upon the X-ray structure of related aspartic acid proteases such as *Rhizopus chinensis* carboxyl proteinase, endothiapepsin, and other aspartic acid proteases. The X-ray structural studies with peptide inhibitors also provided the details of molecular interactions. Based upon this knowledge,











substrate-based inhibitors were developed to mimic the N-terminal portion of angiotensinogen, in which the scissile peptide bond was modified based on the transition-state mimetic concept. Subsequent structure-based optimization of the early renin inhibitors led to the successful modification of inhibitors with improved drug-like properties, resulting in the discovery of aliskiren in 2007, the first FDA-approved renin inhibitor for the treatment of hypertension [30,31].

In the late 1980s, the power of structure-based design was unveiled in the context of the structure-based design and synthesis of HIV protease inhibitors for the treatment of HIV infection and AIDS. The discovery of the key role of HIV protease in the viral life cycle and the documentation that inhibition of the viral HIV-1 protease resulted in noninfectious virions brought hope and urgency to the therapeutic inhibition of HIV protease [32,33]. Knowledge and expertise gained in the design of renin inhibitors, and the determination of the X-ray structure of HIV-1 protease at the early stages of inhibitor design, led to rapid progress in structure-based design capabilities [34]. Within a decade, hundreds of X-ray structures of HIV protease, inhibitor-bound HIV-1 protease, and mutant proteases aided in the design of conceptually novel inhibitors. In this context, numerous tools and concepts have emerged for the design of novel inhibitors and for addressing issues of drug resistance [35,36]. The first HIV-1 protease inhibitor, saquinavir, received FDA approval in 1996. Structure-based drug discovery efforts expanded rapidly in many other areas. As can be seen in Table 1.1, structure-based approaches contributed to the approval of 34 new drugs for the treatment of hypertension, HIV/AIDS chemotherapy, various cancers, and other human diseases through 2012 [37–70].

Structure-based drug design approaches have been widely utilized in the design and development of inhibitors of protein kinases for the treatment of a range of human carcinomas [71–73]. Imatinib was the first example of an anticancer drug specifically directed at inhibiting a drug target Bcr-Abl fusion protein involved in the pathogenesis of chronic myelogenous leukemia. Detailed structural studies of imatinib and Abl kinase complexes provided much molecular insight into imatinib resistance. The lead compound for imatinib was discovered through high-throughput screening (HTS). Lead optimization to improve potency, selectivity, and pharmacokinetic properties led to the discovery of imatinib. The structural studies paved the way for development of other kinase inhibitors. Once protein kinases were recognized as important drug targets for the development of anticancer therapies, much effort was directed toward obtaining structural insight into the binding sites of various protein kinases. X-ray crystallography was central to the understanding of binding mode of various classes of inhibitors. This molecular insight was extensively utilized in the structure-based design of various kinase inhibitor drugs.

The full potential of structure-based design has yet to be realized. Progress in structure-based design of ligands for G-protein-coupled receptors (GPCRs) has been growing steadily [74–77]. The recent evolution of techniques for X-ray crystallography resulted in the determination of novel GPCR structures at a rapid pace. Many high-resolution X-ray structures of ligand-bound GPCRs provided important understanding of the molecular determinants of ligand binding and receptor

Table 1.1 Drugs derived from structure-based design approaches.

 <p>Captopril [37] Approved in 1981 ACE inhibitor (antihypertensive)</p>	 <p>Dorzolamide [38] Approved in 1995 Carbonic anhydrase inhibitor (antiglaucoma)</p>
 <p>Saquinavir [39] Approved in 1995 HIV protease inhibitor (anti-HIV/AIDS)</p>	 <p>Ritonavir [40] Approved in 1996 HIV protease inhibitor (anti-HIV/AIDS)</p>
 <p>Indinavir [41] Approved in 1996 HIV protease inhibitor (anti-HIV/AIDS)</p>	 <p>Brinzolamide [42] Approved in 1999 Carbonic anhydrase inhibitor (antiglaucoma)</p>
 <p>Nelfinavir [43] Approved in 1999 HIV protease inhibitor (anti-HIV/AIDS)</p>	 <p>Amprenavir [44] Approved in 1999 HIV protease inhibitor (anti-HIV/AIDS)</p>
 <p>Lopinavir [45] Approved in 1999 HIV protease inhibitor (anti-HIV/AIDS)</p>	 <p>Zanamivir [46] Approved in 1999 Neuraminidase inhibitor (anti-influenza)</p>

(continued)

Table 1.1 (Continued)

























 <p>Oseltamivir [47] Approved in 1999 Neuraminidase inhibitor (anti-influenza)</p>	 <p>Imatinib [48] Approved in 2001 Chronic myelogenous leukemia</p>
 <p>Gefitinib [49] Approved in 2003 EGFR inhibitor (anticancer)</p>	 <p>Atazanavir [50] Approved in 2003 HIV protease inhibitor (anti-HIV/AIDS)</p>
 <p>Fosamprenavir [51] Approved in 2003 HIV protease inhibitor (anti-HIV/AIDS)</p>	 <p>Erlotinib [52] Approved in 2004 EGFR inhibitor (anticancer)</p>
 <p>Ximelagatran [53] Approved in 2004 Thrombin inhibitor (anticoagulant)</p>	 <p>Sorafenib [54] Approved in 2005 VEGFR inhibitor (anticancer)</p>
 <p>Tipranavir [55] Approved in 2005 HIV protease inhibitor (anti-HIV/AIDS)</p>	 <p>Udenafil [56] Approved in 2005 PDE-5 inhibitor (erectile dysfunction)</p>

Table 1.1 (Continued)

 <p>Sunitinib [57] Approved in 2006 Multikinase inhibitor (anticancer)</p>	 <p>Darunavir [58] Approved in 2006 HIV protease inhibitor (anti-HIV/AIDS)</p>
 <p>Vorinostat [59] Approved in 2006 Histone deacetylase inhibitor (anticancer)</p>	 <p>Dasatinib [60] Approved in 2006 Tyrosine kinase inhibitor (antileukemia)</p>
 <p>Nilotinib [61] Approved in 2006 BCR-ABL kinase inhibitor (antileukemia)</p>	 <p>Aliskiren [62] Approved in 2007 Renin inhibitor (antihypertensive)</p>
 <p>Lapatinib [63] Approved in 2007 Tyrosine kinase inhibitor (anticancer)</p>	 <p>Rivaroxaban [64] Approved in 2008 Factor Xa inhibitor (anticoagulant)</p>
 <p>Dabigatran [65] Approved in 2008 Thrombin inhibitor (anticoagulant)</p>	 <p>Etravirine [66] Approved in 2008 NNRT inhibitor (anti-HIV/AIDS)</p>

(continued)

Table 1.1 (Continued)

 <p>Pazopanib [67] Approved in 2009 Multikinase inhibitor (anticancer)</p>	 <p>Vemurafenib [68] Approved in 2011 B-Raf kinase inhibitor (anticancer)</p>
 <p>Crizotinib [69] Approved in 2011 c-MET and ALK inhibitor (anticancer)</p>	 <p>Ponatinib [70] Approved in 2012 Bcr-Abl inhibitor (antileukemia)</p>

activation, a critical step for designing agonists or antagonists. Recent studies have been aimed at understanding if this structural information can be effectively employed for the structure-based design of novel, potent, and selective GPCR ligands. Structure-based design of novel ligands for GPCRs has become an exciting area of drug development.

1.4

Conclusions

Serendipity and natural product screening may continue to have an important role in drug design, but it is clear that structure-based design strategies are making a significant impact on the drug discovery process. The success of this approach is already evident in 34 FDA-approved drugs on the market through 2012. Numerous other drugs developed using this approach are undergoing clinical trials. No doubt, the success of structure-based design strategies rests heavily on the structural knowledge of disease-relevant target enzymes and their families. The notable success of drug development in the areas of HIV-1 protease, protein kinase, NS3/4A serine protease, and β -secretase greatly empowered the application of these strategies in other areas of drug development. With continual advances in technology and increasing knowledge of disease mechanisms and protein structures, structure-based design strategies will find wide applications in drug discovery endeavors.